Article
Quantitative analysis of MGMT promoter methylation in glioblastoma suggests nonlinear prognostic effect
1 Jan 2023
Abstract excerpt
Abstract Background Epigenetic inhibition of the O6-methylguanine-DNA-methyltransferase (MGMT) gene has emerged as a clinically relevant prognostic marker in glioblastoma (GBM). Methylation of the MGMT promoter has been shown to increase chemotherapy efficacy. While traditionally reported as a binary marker, recent methodological advancements have led to quantitative methods of measuring promoter methylation,...
Topics
Join the communities discussing this publication.